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Alpha-TFEB renal cell carcinoma 
Note 
A distinctive renal neoplasm with epithelioid 




This is a recently described, novel type of renal cel
carcinoma, which is most likely related to the recently-
described and recognized Xp11 renal translocation 
carcinomas. 
Clinics and pathology 
Etiology 
Not clear, but two of 12 confirmed cases have occurred 
in children who were exposed to prior cytotoxic 
chemotherapy, raising the possibility that this tumor 
may be induced by chemotherapy. 
Epidemiology 
There are 12 reported cases, 3 in males and 9 in 
females. The median age is 18 years (range: 6-53 
years). 
Pathology 
On microscopic examination, these neoplasms feature 
nests and tubules of polygonal epithelioid cells, 
separated by thin capillaries. Papillary architecture may 
be seen. The majority of the tumor cells have abundant 
clear to granular eosinophilic cytoplasm, well-defin d 
cell borders and round nuclei with small nucleoli. 
However, a second population of smaller epithelioid 
cells is also characteristic, typically (but not alw ys) 
clustered around nodules of hyaline basement 
membrane material within larger acini. Mitoses are r r  
and necrosis is usually absent. The cases examined 
have generally been negative for cytokeratins by 
immunohistochemistry, but all have labeled at least 
focally for HMB45 and Melan A. We have recently 
found that the t(6;11) renal carcinomas demonstrate 
specific nuclear labeling for TFEB protein by IHC 
while other neoplasms and normal tissues do not. 
Hence, nuclear labeling for TFEB is a sensitive and 
specific diagnostic marker for this renal neoplasm with 




Unclear at the current time. One case has metastasized 
and killed the patient, proving that these are malign nt 
neoplasms. 














DNA / RNA 
TFEB has 10 exons, with the ATG protein initiation 




TFEB is a transcription factor with a basic helix-loop-
helix DNA binding domain, a leucine zipper 
dimerization domain18, and a nuclear localization 
signal, thought to be located C-terminal to the helix-
loop-helix domain. TFEB is ubiquitously expressed. 
TFEB, TFE3, TFEC and Mitf comprise the members of 
the microphthalmia transcription factor subfamily, 
which have homologous DNA binding domains and 
can bind to a common DNA sequence.  
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These four transcription factors may homo- or 





DNA / RNA 
Alpha is an intronless, untranslated gene of unknown 
function. 




The breakpoint on TFEB is within its second intron, 
just upstream of the TFEB initiation ATG codon, 
which results in retention of the entire TFEB coding 
region in the fusion gene. Although the Alpha promoter 
drives expression of the fusion gene, the Alpha gene 
does not contribute to the open reading frame. 
Therefore, the consequence of the Alpha-TFEB fusion 
is dysregulated expression of the normal full-length 
TFEB protein. The TFEB-Alpha fusion gene is also 
expressed. 
Detection 
RT-PCR is the standard molecular approach for 
detection of most translocation-associated gene fusions. 
This is because, in most leukemia and sarcoma 
translocations, genomic breakpoints are variably 
positioned within large introns, but the splicing of the 
transcripts encoded by fusion genes typically results in 
very consistent fusion points that can be tightly 
bracketed by appropriate primers to generate relativ ly 
small RT-PCR products (e.g. 100-300 bp). 
In the t(6;11)(p21;q12), the lack of splicing between 
Alpha and TFEB results in a different and unique 
fusion transcript in each case that can vary considerably 
in size (over 1 kb) from case to case. Since RNAs 
extracted from clinical samples are usually partially 
degraded, amplification of targets in this size range is 
much more inefficient and the risk of false-negatives 
correspondingly increases. The Alpha fusion points in 7 
fully characterized tumors were scattered over 1.2 kb. 
Because there are likely no functional consequences to 
different fusion points in Alpha (since it does not 
encode a native protein or a fusion protein with TFEB), 
additional Alpha fusion points outside of this 
breakpoint cluster region may well be found in the 
future. The fusion points in TFEB appear more tightly 
clustered; so far, all have been located in a 167 bp 
region near the 3’ end of intron 2. Based on the siz s of 
these two breakpoint cluster regions, RT-PCR product 
sizes using a primer at the 5’ end of Alpha in 
combination with a reverse primer in exon 3 of TFEB  
could range in size to over 1.5 kb. This is a technical 
drawback for molecular diagnosis that could be 
addressed by using several assays with different Alpha 
primers scattered from the 5’ to the 3’ end of the gene. 
However the unique features of the Alpha gene as a 
translocation partner should result in a lack of splicing 
across the intron rearranged by the translocation. 
Indeed, this seems to be the case, since in all three 
cases with data on both the genomic junction sequence 
and the fusion transcript, the sequences have been 
identical. This indicates that the DNA PCR and RT-
PCR products will be identical if a reverse primer that 
binds to TFE3 exon 3 is used. Because it is easier to 
isolate and amplify 1 to 1.5 kb target DNAs from 
clinical tumor samples than target RNAs of the same 
size (given the greater lability of RNA), detecting this 
fusion by long range DNA PCR may be a useful 
alternative for molecular diagnosis. 
Fusion Protein 
Note 
The Alpha-TFEB gene fusion results in dysregulated 
expression of native TFEB protein. 
Expression / Localisation 
TFEB protein that is overexpressed as a result of the 
Alpha-TFEB gene fusion localizes to the nucleus as 
determined by immunohistochemistry. While it is 
ubiquitously expressed, native TFEB in cells without 
this translocation is not detectable by this assay. 
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